Welcome!

News Feed Item

Personal Genome Diagnostics' Circulating Tumor DNA Technology Highlighted In Landmark Study

--New Publication in Science Translational Medicine Confirms Utility of Cell-Free Circulating Tumor DNA (ctDNA) for Cancer Drug Development and Diagnosis--

BALTIMORE, Md., Feb. 19, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published today in the journal Science Translational Medicine. The study, "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies," assessed the utility of cell-free circulating tumor DNA (ctDNA) for cancer detection and monitoring across multiple patient populations and applications. The authors conclude that ctDNA is a broadly applicable, sensitive and specific biomarker that can be used for a variety of clinical and research purposes in patients with different types of cancer.1

Some of the findings reported today were analyzed using PGDx's proprietary PARE technology, an ultrasensitive technique that enables whole genome identification of changes in tumor-specific ctDNA. The new findings are consistent with previous publications by PGDx researchers and further validate the company's work using ctDNA-based analyses for cancer research and drug development.

"This landmark study further validates the utility of circulating DNA as a biomarker in cancer therapeutic research and treatment," noted Mark Sausen, PhD, a lead author of the new study and Director of R&D at PGDx. Dr. Sausen was one of the first researchers to use genome-wide analyses of ctDNA to identify newly-acquired genetic alterations associated with resistance to targeted therapies.

Dr. Sausen added, "At PGDx, we have experienced a surge of interest in ctDNA-based analyses and are now using our PARE and related technologies to routinely perform genetic analyses on ctDNA, thereby obviating the need for invasive biopsies. Genomic analyses conducted using ctDNA produce a great deal of information, including detection of structural genomic alterations and point mutations, which makes them very valuable for the development of targeted cancer therapies."

Unlike other approaches, which can detect point mutations in ctDNA, PARE (Personalized Analysis of Rearranged Ends) can also detect structural changes, including the genomic amplifications and rearrangements that are critical for guiding cancer treatment. PGDx has licensed exclusive rights to the PARE technology from Johns Hopkins University.

The study in Science Translational Medicine addressed several topics related to ctDNA. The first assessed the extent to which ctDNA could be detected in different cancer populations at various stages of disease. It found ctDNA was detectable in many, but not all types of advanced solid tumor cancers, as well as in many individuals with earlier-stage localized tumors. The study also found that cell-free ctDNA often was detectable in patients who lacked circulating tumor cells, providing further validation of PGDx's ctDNA approach.

The new study also found that ctDNA could be used to identify known and novel genetic mutations associated with drug resistance in patients with colorectal cancer. PGDx has previously published research showing that its PARE ctDNA approach2,3, which can detect structural alterations in ctDNA with high sensitivity and specificity, was able to identify novel mechanisms of acquired drug resistance from the blood of a colorectal cancer patient being treated with targeted therapy. These analyses enabled the new genetic alteration to be identified before any clinical signs of drug resistance were evident, providing early warning that a change in therapy was needed.

Antony Newton, Chief Commercial Officer of PGDx, added, "This new study confirms the value of our expertise in the application of cell-free circulating tumor DNA technologies. We are already offering these technologies for both prospective and retrospective clinical trial applications and expect this new study will accelerate the growing interest in the use of ctDNA for drug development."

Along with Dr. Sausen, co-authors of the new study include PGDx co-founders and Johns Hopkins cancer researchers Dr. Luis Diaz and Dr. Victor Velculescu.

1. Science Translational Medicine. 2014 February 19; 6 (224): Detection of circulating tumor DNA in early- and late-stage human malignancies. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, l.-M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr.

2. Oncotarget. 2013 October; 4(10): 1856–1857. PMCID: PMC3858570. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Luis A. Diaz, Jr., Mark Sausen, George A. Fisher, and Victor E. Velculescu.

3. Cancer Discovery. 2013 June; 3 (6): 658-73. doi: 10.1158/2159-8290.CD-12-0558. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr., Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors.  PGDx's proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. The founders of PGDx, Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics at Johns Hopkins University who have extensive experience in the practical application of advanced genomic technologies to drug development and clinical practice. PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.

Contacts:


Personal Genome Diagnostics

Media:

Antony Newton

BLL Partners, LLC

Chief Commercial Officer 

Barbara Lindheim

410 849-9189

212 584-2276

[email protected] 

[email protected]

SOURCE Personal Genome Diagnostics Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Digital transformation is too big and important for our future success to not understand the rules that apply to it. The first three rules for winning in this age of hyper-digital transformation are: Advantages in speed, analytics and operational tempos must be captured by implementing an optimized information logistics system (OILS) Real-time operational tempos (IT, people and business processes) must be achieved Businesses that can "analyze data and act and with speed" will dominate those t...
The Jevons Paradox suggests that when technological advances increase efficiency of a resource, it results in an overall increase in consumption. Writing on the increased use of coal as a result of technological improvements, 19th-century economist William Stanley Jevons found that these improvements led to the development of new ways to utilize coal. In his session at 19th Cloud Expo, Mark Thiele, Chief Strategy Officer for Apcera, will compare the Jevons Paradox to modern-day enterprise IT, e...
There are several IoTs: the Industrial Internet, Consumer Wearables, Wearables and Healthcare, Supply Chains, and the movement toward Smart Grids, Cities, Regions, and Nations. There are competing communications standards every step of the way, a bewildering array of sensors and devices, and an entire world of competing data analytics platforms. To some this appears to be chaos. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Bradley Holt, Developer Advocate a...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
SYS-CON Events announced today that ReadyTalk, a leading provider of online conferencing and webinar services, has been named Vendor Presentation Sponsor at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. ReadyTalk delivers audio and web conferencing services that inspire collaboration and enable the Future of Work for today’s increasingly digital and mobile workforce. By combining intuitive, innovative tec...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...